Company Performance - AtriCure reported a quarterly loss of $0.02 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.17 per share a year ago, resulting in an earnings surprise of +86.67% [1] - The company achieved revenues of $136.14 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.61% and showing a year-over-year increase from $116.27 million [2] - Over the last four quarters, AtriCure has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - AtriCure shares have increased approximately 8.7% since the beginning of the year, slightly outperforming the S&P 500's gain of 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $129.12 million, and for the current fiscal year, it is -$0.50 on revenues of $522.61 million [7] Industry Context - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of AtriCure's stock may be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

分组1 - Exagen Inc. reported a quarterly loss of $0.18 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.16 per share a year ago [1] - The company posted revenues of $17.2 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 7.51%, and up from $15.06 million year-over-year [2] - Exagen shares have increased approximately 80.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] 分组2 - The earnings outlook for Exagen is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Exagen was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $16.5 million, and -$0.61 on revenues of $65.8 million for the current fiscal year [7] 分组3 - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, which may impact stock performance [8] - Cresco Labs Inc., another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +75%, with revenues projected at $163.86 million, down 11.1% from the previous year [9]

Core Viewpoint - Tilray Brands, Inc. reported quarterly earnings of $0.02 per share, surpassing the Zacks Consensus Estimate of a loss of $0.03 per share, marking an earnings surprise of +166.67% [1] - The company posted revenues of $224.54 million for the quarter ended May 2025, which was 6.46% below the Zacks Consensus Estimate and a decrease from $229.88 million year-over-year [2] Financial Performance - The earnings report indicates a significant improvement from a loss of $0.04 per share a year ago [1] - Over the last four quarters, Tilray Brands has exceeded consensus EPS estimates twice, but has not beaten revenue estimates during the same period [2] Stock Performance - Tilray Brands shares have declined approximately 48.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Tilray Brands is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $209.71 million, and for the current fiscal year, it is -$0.17 on revenues of $885.29 million [7] - The outlook for the Medical - Products industry, to which Tilray Brands belongs, is currently in the bottom 30% of Zacks industries, which may negatively impact stock performance [8]

Core Insights - ResMed is positioned to continue its earnings-beat streak, having surpassed earnings estimates in the last two quarters by an average of 3.04% [1][5] - The company reported earnings of $2.36 per share for the most recent quarter, slightly below the expected $2.37, but still achieved a surprise of 0.42% [2] - In the previous quarter, ResMed exceeded the consensus estimate of $2.30 per share by reporting $2.43, resulting in a surprise of 5.65% [2] Earnings Estimates and Predictions - Recent estimates for ResMed have been increasing, with a positive Earnings ESP of +5.16%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9] Importance of Earnings ESP - Companies often beat consensus EPS estimates, but this is not the only factor influencing stock price movements; thus, checking the Earnings ESP is crucial for investment decisions [10]

Company Overview - Valneva SE Sponsored ADR (VALN) shares increased by 17.4% to $7.32 in the last trading session, with a notable trading volume that exceeded the average [1] - The stock has gained 11.3% over the past four weeks, indicating a positive trend [1] Market Sentiment - The rise in VALN shares is attributed to positive market sentiment driven by recent regulatory successes and strong momentum in the biotech sector [2] - Investor confidence was bolstered by the European Medicines Agency (EMA) lifting age-based restrictions on Valneva's chikungunya vaccine, reflecting increasing regulatory support [2] Financial Expectations - Valneva is projected to report a quarterly loss of $0.27 per share, which is a year-over-year improvement of 27% [3] - Expected revenues for the upcoming quarter are $55.89 million, representing a 36.4% increase compared to the same quarter last year [3] Earnings Estimates - The consensus EPS estimate for Valneva has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, indicating the importance of monitoring future earnings updates [4] Industry Context - Valneva is categorized within the Zacks Medical - Products industry, which includes other companies like GE HealthCare Technologies (GEHC) [5] - GEHC shares increased by 1% to $77.25, with a 6.3% return over the past month, indicating a positive trend in the same industry [5] GE HealthCare Overview - GE HealthCare's consensus EPS estimate for the upcoming report is $0.91, reflecting a 9% decrease from the previous year [6] - GE HealthCare also holds a Zacks Rank of 3 (Hold), similar to Valneva [6]

Core Viewpoint - Boston Scientific (BSX) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1][6]. Earnings Performance - The company has a solid track record of surpassing earnings estimates, with an average surprise of 9.82% over the last two quarters [2]. - In the last reported quarter, Boston Scientific achieved earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.67 per share by 11.94% [3]. - For the previous quarter, the company reported earnings of $0.70 per share against an expectation of $0.65 per share, resulting in a surprise of 7.69% [3]. Earnings Estimates and Predictions - Recent estimates for Boston Scientific have been trending upward, indicating positive sentiment among analysts [6]. - The Zacks Earnings ESP for the company is currently +0.88%, suggesting increased bullishness regarding its near-term earnings potential [9]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a strong likelihood of another earnings beat [9]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [8].

Core Viewpoint - Agilent Technologies has seen a 5.4% increase in share price over the past month, outperforming the S&P 500, but there are concerns about whether this positive trend will continue leading up to the next earnings release [1] Estimates Movement - Estimates for Agilent have trended downward over the past month, indicating a negative shift in expectations [2] VGM Scores - Agilent currently holds a subpar Growth Score of D and a similar score for momentum, with a value grade of C, placing it in the middle 20% for this investment strategy; the overall aggregate VGM Score is D [3] Outlook - The downward trend in estimates suggests a negative outlook, although Agilent maintains a Zacks Rank 2 (Buy), indicating expectations for above-average returns in the coming months [4] Industry Performance - Agilent is part of the Zacks Medical - Products industry, where Medtronic has gained 4.6% over the past month; Medtronic reported revenues of $8.93 billion for the last quarter, reflecting a year-over-year increase of 3.9% [5] - Medtronic's expected earnings for the current quarter are $1.23 per share, unchanged from the previous year, with a Zacks Rank 4 (Sell) and a VGM Score of B [6]

Company Overview - Brainsway Ltd. shares (BWAY) experienced a 5.3% increase, closing at $11.49, with notable trading volume compared to typical sessions [1] - The company is expected to report quarterly earnings of $0.04 per share, unchanged from the previous year, with revenues projected at $12.39 million, reflecting a 23.8% increase year-over-year [3] Clinical Trial Results - The recent rise in BWAY shares is linked to positive market sentiment following successful clinical trial results for BrainsWay's accelerated Deep TMS therapy for Major Depressive Disorder (MDD) [2] - The multicenter, randomized study showed statistically significant improvements in depression symptoms, a favorable safety profile, and rapid onset of effect, positioning BrainsWay's technology as a leading non-invasive treatment option for MDD [2] Earnings Estimates and Market Sentiment - The consensus EPS estimate for Brainsway has been revised 10% higher in the last 30 days, indicating a positive trend that typically correlates with price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [5] Industry Comparison - Brainsway operates within the Zacks Medical - Products industry, where Boston Scientific (BSX) also competes, having closed 1.1% higher at $102.36, but with a -3.1% return over the past month [5] - Boston Scientific's consensus EPS estimate has increased by 0.1% to $0.72, representing a 16.1% change compared to the previous year [6]

Company Overview - Medtronic shares have increased by approximately 6% over the past month, outperforming the S&P 500 index [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Medtronic have trended downward, with a consensus estimate shift of -6.38% in the past month [2] - The overall direction of estimate revisions indicates a negative outlook for the stock [4] VGM Scores - Medtronic has a Growth Score of B, a Momentum Score of F, and a Value Score of C, resulting in an aggregate VGM Score of C [3] Market Outlook - The downward trend in estimates has led to a Zacks Rank of 4 (Sell) for Medtronic, suggesting expectations of below-average returns in the coming months [4] Industry Comparison - Medtronic is part of the Zacks Medical - Products industry, where Phibro Animal Health (PAHC) has gained 4.1% over the past month [5] - Phibro reported revenues of $347.8 million for the last quarter, reflecting a year-over-year increase of +32.1% [5] - Phibro's expected earnings for the current quarter are $0.52 per share, indicating a +26.8% change from the previous year, with a Zacks Rank of 1 (Strong Buy) [6]

Company Performance - High Tide Inc. reported a quarterly loss of $0.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, marking an earnings surprise of -50% [1] - The company posted revenues of $96.94 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.22% and showing an increase from year-ago revenues of $91.6 million [2] - Over the last four quarters, High Tide has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] Stock Performance - High Tide shares have declined approximately 26.2% since the beginning of the year, contrasting with the S&P 500's gain of 1.6% [3] - The current Zacks Rank for High Tide is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $102.27 million, and for the current fiscal year, it is -$0.07 on revenues of $404.52 million [7] - The estimate revisions trend for High Tide is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - High Tide operates within the Zacks Medical - Products industry, which is currently ranked in the bottom 37% of over 250 Zacks industries [8] - The performance of stocks in this industry can be significantly influenced by the overall industry outlook, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]